Table 4 Core Gene Pathway Alterations and Association with Patients’ Survival in Resectable KRAS^mut PDAC

KRAS 

 G12D

220 (48.0%)

11.83 [9.65–14.01]

1 [Reference]

1

21.07 [18.49–23.65]

1 [Reference]

1

 Other codon

238 (52.0%)

13.97 [11.93–16.01]

0.823 [0.663–1.020]

0.075

23.30 [21.79–24.81]

0.839 [0.665–1.059]

0.139

TP53

 WT

164 (35.8%)

17.30 [14.88–19.72]

1 [Reference]

1

26.97 [20.98–32.96]

1 [Reference]

1

  Mutated

294 (64.2%)

10.60 [9.14–12.06]

1.390 [1.102–1.752]

0.005

21.03 [18.54–23.52]

1.287 [1.003–1.651]

0.047

Cell cycle

 WT

376 (82.1%)

13.90 [11.70–16.10]

1 [Reference]

1

23.30 [21.19–25.41]

1 [Reference]

1

 Mutated

82 (17.9%)

10.60 [7.97–13.23]

1.388 [1.059–1.818]

0.017

19.23 [16.33–22.13]

1.385 [1.034–1.855]

0.029

TGFb

 WT

365 (79.7%)

13.63 [11.54 – 15.72]

1 [Reference]

1

23.23 [21.19–25.27]

1 [Reference]

1

 Mutated

93 (20.3%)

10.07 [7.01 - 13.13]

1.201 [0.929–1.552]

0.162

18.77 [14.42–23.12]

1.165 [0.883–1.537]

0.280

Trithorax

 WT

362 (79.0%)

12.93 [10.96 - 14.90]

1 [Reference]

1

22.43 [20.54–24.32]

1 [Reference]

1

 Mutated

96 (21.0%)

12.83 [9.76 - 15.90]

0.917 [0.705–1.193]

0.519

23.10 [20.18–26.02]

0.903 [0.656–1.243]

0.532

Male

273 (59.6%)

1.198 [0.966–1.485]

0.099

1.153 [0.912–1.458]

0.233

Age > 70y

108 (23.6%)

1.070 [0.814–1.407]

0.627

1.061 [0.785–1.435]

0.699

Vascular invasion

159 (34.7%)

1.209 [0.952–1.537]

0.120

1.243 [0.962–1.604]

0.096

Poor differentiated

228 (49.8%)

1.573 [1.270–1.949]

<0.001

1.645 [1.303–2.076]

<0.001

Tumor >3cm

170 (37.1%)

1.439 [1.139–1.816]

0.002

1.336 [1.046–1.706]

0.020

N1-2

240 (52.4%)

1.412 [1.140–1.749]

0.002

1.497 [1.189–1.885]

0.001

R1 margin status

72 (15.7%)

1.211 [0.902–1.625]

0.203

1.395 [1.024–1.899]

0.035

Chemotherapy

329 (71.8%)

0.571 [0.443–0.736]

<0.001

0.042 [0.304–0.531]

<0.001